9-19 | Ahead of the global tuberculosis High-Level Meeting at the United Nations, MSF calls on Johnson & Johnson not to enforce any secondary patents for bedaquiline in any country with a high burden of TB.We also call on Cepheid to drop the price of the GeneXpert TB test from US$10 to US$5 in order to save lives.
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla
2-17 | CAPE TOWN - A vaccination support programme developed by MSF in Khayelitsha, South Africa, in partnership with the Western Cape Department of Health (WCDoH), has shown that it is possible to target and protect individuals with comorbidities that increase the risk of severe disease and death from COVID-19.
11-4 | Following the release of US pharmaceutical company Moderna’s astronomical third quarter 2021 sales figures from its only product, the COVID-19 vaccine, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the company to immediately share its mRNA vaccine technology and know-how through the World Health Organization's (WHO) COVID-19 mRNA vaccine technology transfer Hub in South Africa.